Original article
Survey of research-based pharmaceutical companies represented on the MVF advisory board (carried out: April/May 2019). Written survey on the status of RWE study projects that have already been carried out. Pfizer Germany (Friedhelm Leverkus), Sanofi-Aventis Germany (Dr.-Ing. Janine Garbe, MHBA), Novartis Pharma (Dr. Andreas Kress) and Roche Pharma (Dr. Susanne Schach) responded.
04.04.2019
While the newly founded task force of the Heads of Medicines Agencies of the EMA (see p. 12 ff.) is dealing with the question of which real world data, in what quality and with which standards, are necessary to use this data for the management of the healthcare system To use this, the FDA has already presented a detailed “Framework for FDA's Real-World Evidence Program”, with which the US regulatory authority has developed a concept for integrating real-world data (see p. 14 ff.). A number of real-world evidence studies have already been carried out internationally, but in Germany this topic still seems to be of a certain concern. “Monitor Health Services Research” spoke to Dr. Marco Penske, Head Market Access & Healthcare Affairs at Boehringer Ingelheim Pharma GmbH & Co. KG; and secondly asked some research-based pharmaceutical companies represented on the advisory board for information about the status of RWE study projects that have already been carried out.
04.04.2019
“The great opportunity of the future,” says Prof. Dr. Frank Jessen, Director of the Clinic and Polyclinic for Psychiatry and Psychotherapy at the University Hospital of Cologne, the model of Disease Interception. Many authors and interlocutors who speak in the specialist book of the same name – published in the “Monitor Healthcare Research” (MVF) series – find similarly strong comparisons. “A bold and hopeful vision,” for example, is what MVF editor Prof. Dr. Reinhold Roski in his editorial describes this “promising concept” (quote from Prof. Dr. Dr. Eva Winkler, senior physician at the National Center for Tumor Diseases and head of the research focus “Ethics and patient orientation in oncology), which “represents the most fervent wish of all affected patients and Patients” (Dr. Martin Danner, BAG) could make health instead of illness come true. Above all, because this “bet on a better future” (Wasem) has the potential to become “an established repair shop after centuries of medicine,” as Prof. Dr. Jochen A. Werner, Medical Director and Chairman of the Board of the Essen University Medical Center, states in his contribution that he is “opening a new chapter”.
04.04.2019
Benefit assessment needs new, European approaches. The processes are too complex and opaque, and patient preferences are not taken into account enough. At the fifth plenary event “Benefit Assessment 2.0 – European Standards for Patient Benefit?” in June 2019, experts in Berlin discussed decision-making criteria and the necessary steps for the uniform assessment of innovative therapies, medications and medical devices.
04.04.2019
The founding of the Bergisches Competence Center for Health Economics and Health Care Research - originally the Bergisches Competence Center for Health Management and Public Health - (BKG) in 2009 was based on the conviction that health is a central value. The guiding principle behind its creation was to design future-proof care together with those involved in the local health system and economy. Since then, the interdisciplinary center has been an integral part of the Schumpeter School of Business and Economics at the University of Wuppertal and a supporting pillar of the profile line “Health, Prevention and Exercise” at the University of Wuppertal. The working group “Health Care Research and Health Economic Evaluation” was initiated at the BKG in 2010 and has since been led by Professor Dr. Juliane Köberlein-Neu directed.
04.04.2019
“Against this background, the question arises as to how Cochrane as an organization deals with such members,” wrote Prof. Dr. Gerd Antes, who looks back on almost 25 years of experience as a member of the Cochrane Organization (including a member of the Steering Group and Director of the German Cochrane Center until 2018) in a blog1: The reason for his intervention was the dismissal of Dr. Peter C. Gøtzsche, one of the founding members of the collaboration and not only long-time director of the Nordic Cochrane Center in Copenhagen, but also, according to Antes, one of the Cochrane authors with a veritable “wealth of articles and books as well as analyzes on many of today's explosive topics Health research and care”.
04.04.2019
The BMC board explains the seven points that the pluralistic association with its over 200 members would like to bring into the discussion on the occasion of the Digital Supply Act (DVG) passed by the Federal Cabinet on July 10th. For this purpose, board members and management met at the last BMC board meeting.
04.04.2019
Comment from Dr. Ilona Köster-Steinebach, managing director of the Aktionsbündnis Patient Safety eV
04.04.2019
Prof. Dr. Jochen Schmitt, congress president of the German Congress for Health Care Research (DKVF), which is taking place for the 18th time this year, and director of the Center for Evidence-Based Health Care (ZEGV) at the University Hospital Dresden, takes a position on the major task of health care research that lies ahead: the support and promotion of transfer effective concepts and interventions from research into routine care, with the help of which a learning health system can be created.
04.04.2019
“The SELFIE Framework for Integrated Care for Multi-Morbidity”, “Task shifting between doctors and nurses in acute care hospitals: cross-sectional study in nine countries”, “Hospital: Impulses from Denmark for Germany”. This is how three of the 33 publications are titled, which Prof. Dr. med. Reinhard Busse and his team published last year alone, and in 2017 there were 37. This means that the “Management in Health Care” (MiG) department at the Technical University of Berlin (TU) is one of the most published in Germany, especially in international journals. This is of course also due to the fact that internationality is not a slogan at MiG, but rather a program: Since 2002, MiG has been led by Busse, whom Richard Lane from the Lancet described in an author profile as a “leader in Germany's health-system development”. national and international research projects on topics from health policy and systems, health services research, health economics and management as well as the assessment of health technologies (Health Technology Assessment - HTA).